SCHEMBL13879449

SCHEMBL13879449

O=C1NC(Cc2c[nH]c3ccccc23)C(=O)N1Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 1.00
MEN1 O00255 4/20 0.93
L3MBTL1 Q9Y468 2/20 0.93
TNF P01375 3/20 0.84
MAPT P10636 2/20 0.73
RAB9A P51151 1/20 0.72
TACR1 P25103 1/20 0.65
LMNA P02545 3/20 0.64
PKM P14618 1/20 0.64
POLB P06746 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.59
TP53 P04637 1/20 0.58
GLA P06280 1/20 0.58
CYP3A4 P08684 1/20 0.58
THRB P10828 1/20 0.58
IDO1 P14902 1/20 0.58
RIPK1 Q13546 1/20 0.58
HSD17B10 Q99714 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5528722 0.92 TNF (1.00) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL5531669 0.91 L3MBTL1 (1.00) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL838180 0.85 KMT2A (0.75) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL17830374 0.83 TNF (0.82) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL25154850 0.82 KMT2A (0.69) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL7827097 0.81 KMT2A (0.68) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL7815529 0.81 KMT2A (0.68) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL4287307 0.81 HDAC1 (0.75) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL7822959 0.81 HDAC1 (0.75) KMT2AMEN1L3MBTL1TNFMAPT
SCHEMBL11639246 0.80 NPSR1 (0.73) KMT2AMEN1L3MBTL1TNFMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 KMT2A 2463/4885MEN1 4395/4885L3MBTL1 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.